AMRIF, Alloksys’s sister company is readying up for trials in several chronic inflammatory disease applications. Among these diseases are unmet medical need applications in Neurodegenerative diseases Parkinson and Alzheimer as well in several complications from diabetes. Protocols, clinicians, clinical centers, specialty institutes and patients have committed to participate in these studies. The studies will start provided appropriate funds can be secured. A study in RA patients, based on excellent results with hRESCAP® in a first and only animal model for arthritides is prepared as well. Please see www.AMRIF.eu and publication Chandrupatla DMSH,et al 2018 Prophylactic and therapeutic activity of alkaline phosphatase in arthritic rats: single-agent effects of alkaline phosphatase and synergistic effects in combination with methotrexate.Transl Res. 2018 Sep;199:24-38. doi: 10.1016/j.trsl.2018.04.001. Epub 2018 May 17.
Alloksys announces first patients enrolled in the continuation of the APPIRED III clinical trial with RESCAP® in patients undergoing cardiothoracic surgery
October 1, 2024. Alloksys anticipates that in the just started continuation of the APPIRED III study (a placebo-controlled combined phase IIb / III trial), with